Share price · KARD
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when KARD's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 6 Nov 2026+12.0%
- 6 Oct 2026-11.5%
Nothing announced by KARD that day or the session before.
- 2 Sep 2026+11.8%
Nothing announced by KARD that day or the session before.
Share of unusual movement by asset
For each asset, the share of KARD's own-move activity since 22 Jun 2026 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
| Other company news (earnings, financing, releases naming no asset) | — | 14% |
| Sessions with no dated event | — | 86% |
No dated announcements about its assets since 22 Jun 2026.
Assets
(2 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | Cardiac myosin (activator)Small molecule | Heart Failure | |
| Phase 2 | Angiotensinogen (AGT)RNA / oligonucleotide | Hypertension |
Upcoming events
(3 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (1)
December 2026 (1)
What to watch
2027 (1)
September 2027 (1)
What to watch
2032 (1)
November 2032 (1)
What to watch
Financial reports
Quarterly & interim (5)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | — | $64M | $79M+ $393M short-term inv. | $59M-$60M operating cash flow | report ↗ |
View 4 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | — | $56M | $385M+ $214M short-term inv. | $116M | report ↗ |
| 2026-Q1 | — | — | $287M | $56M | report ↗ |
| 2025-Q3 | — | $49M | $170M | $60M-$47M operating cash flow | report ↗ |
| 2025-Q2 | — | $36M | $91M | $57M | report ↗ |
Annual history (2 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | — | $153M | —+ $227M short-term inv. | $192M | report ↗ |
Kardigan reported R&D spend of $153M and a quarterly net burn of $191.9M for fiscal year 2025.
Figures only: this period's report disclosed no narrative text
View 1 more year
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | — | — | $50M | — | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 3 purchases ($90.0M), 0 sales ($0). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-09-29 | Reinke Kristin Marie K · director | Award / grant (derivative) | 48,368 | — | — | Form 4 |
| 2026-06-22 | ARCH Venture Partners XIII, LLC; ARCH Venture Partners XIII, L.P.; ARCH Venture Fund XIII, L.P.; CRANDELL KEITH; NELSEN ROBERT; Burow Kristina; GILLIS STEVEN · director, 10% owner; director, 10% owner; director, 10% owner; director, 10% owner; director, 10% owner; director, 10% owner; director, 10% owner | Open-market purchase | 1,250,000 | $16.00 | $20.0M | Form 4 |
| 2026-06-22 | BERNS PAUL L · director, 10% owner | Open-market purchase | 1,250,000 | $16.00 | $20.0M | Form 4 |
| 2026-06-22 | HRTG GPE, LLC; HRTG PV, L.P.; HRTG CIF 2024, L.P.; Kelly Kevin Anthony; Johnson Keith Bryon · 10% owner; 10% owner; 10% owner; 10% owner; 10% owner | Open-market purchase | 3,125,000 | $16.00 | $50.0M | Form 4 |
| 2026-06-17 | PERCEPTIVE ADVISORS LLC; PERCEPTIVE LIFE SCIENCES MASTER FUND LTD; Perceptive Capital Solutions Holdings LP; EDELMAN JOSEPH · director; director; director; director | Award / grant | 20,706 | — | — | Form 4 |
| 2026-06-17 | Edelberg Jay · Chief Medical Officer | Conversion | 97,587 | — | — | Form 4 |
| 2026-06-17 | Giordano Douglas E. · director | Award / grant | 20,706 | — | — | Form 4 |
| 2026-06-17 | GIANAKAKOS ANASTASIOS · director, President & CEO | Conversion | 28,702 | — | — | Form 4 |